Immune checkpoint inhibitors (ICIs), which are monoclonal antibodies (mAbs) against programmed cell death protein 1 (PD1), have revolutionized the field of cancer immunotherapy (Ganesh et al., 2019). This evidence concerns the gene PDCD1 and cancer.